Results 41 to 50 of about 46,312 (227)
PLoS ONE, 2019 BackgroundIdarucizumab is a humanized Fab fragment that specifically reverses dabigatran anticoagulation. In trauma, volume expanders are used for resuscitation to compensate for blood loss and hemorrhagic shock, but it is unknown whether volume ...
Oliver Grottke +7 more
doaj +1 more source
Archives of Pharmacy Practice, 2016 Warfarin is recognized as the standard antithrombotic agent for stroke prevention. However, new oral anticoagulant such as dabigatran constitutes huge improvement to compensate for the limitation of warfarin.
Amal K Sulieman
doaj +1 more source
How we treat bleeding associated with direct oral anticoagulants [PDF]
, 2016 Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo +4 more
core +1 more source
British Journal of Clinical Pharmacology, 2020 Our study aimed to determine the impact of genetic polymorphisms of ABCB1 and CES1 on the pharmacokinetics (PK) and pharmacodynamics (PD) of dabigatran in patients with nonvalvular atrial fibrillation (NVAF).
Qiuyi Ji +5 more
semanticscholar +1 more source
The new way of Dabigatran reversal – Idarucizumab
Journal of Education, Health and Sport, 2019 Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański +3 more
doaj +3 more sources
Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
Trauma Case Reports, 2021 Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle +4 more
doaj +1 more source
More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]
, 2018 © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M +6 more
core +3 more sources
Determination of Dabigatran Concentration in Human Plasma and Breast Milk
International Journal of Analytical Chemistry, 2021 Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk
F. Sidgwick +4 more
doaj +1 more source
Journal of Prescribing Practice, 2020 In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of tweets. This month she is talking about #dabigatran
openaire +2 more sources
, 2020 In a modern observational study based on healthcare databases, the number of observations and of predictors typically range in the order of $10^5$ ~ $10^6$ and of $10^4$ ~ $10^5$.
Nishimura, Akihiko, Suchard, Marc A.
core +1 more source